Lungscreen Australia have tapped Annalise.ai to power their clinical decision-support technology.
Lungscreen Australia has announced its plans to use Annalise.ai technology as part of its clinical workflows.
The organisation, which claims to be the country’s largest lung screening setup, will use Annalise Enterprise CXR, the Harrison.ai-developed radiology solution, to “enhance diagnostic accuracy, streamline radiology workflows, and ensure faster, more precise lung disease detection” by detecting over 120 different findings on chest x-rays.
Dr Siavash Es’haghi, CEO and managing director at Lungscreen Australia, said it was vital that the organisation had the ability to screen for critical and time-sensitive pathologies with the highest level of accuracy.
“AI is transforming lung screening, helping us catch life-threatening diseases earlier. Annalise Enterprise CXR provides a critical safeguard, ensuring no detail is overlooked in our mission to save lives,” said Dr Es’haghi.
Related
Aengus Tran, co-founder and CEO of Annalise.ai, was proud to support Lungscreen Australia in delivering a high-quality, AI-powered screening approach that will speed up care for Australians at risk of lung disease.
“This partnership marks a step forward in making AI-assisted lung screening more accessible and effective nationwide. Together, Annalise.ai and Lungscreen Australia are setting new standards for early disease detection and patient care,” he said.
